Immunotherapy after progression to double immunotherapy: Pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Category Primary study
JournalImmuno-Oncology and Technology
Year 2024
This article has no abstract
Epistemonikos ID: 11968fb37b26870f5c856cc00e8f28094e263de9
First added on: Feb 19, 2025